Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP

Executive Summary

Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.

You may also be interested in...



Who's Who In The New OHOP

FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion

The Office of Medical Policy now houses the Office of Prescription Drug Promotion (formerly DDMAC) and the newly created Office of Medical Policy Initiatives.

Genentech Restricts Population In Last-Ditch Bid To Keep Avastin's Breast Cancer Claim

Final submission from Genentech focuses on revised indication and Risk Evaluation and Mitigation Strategy to support continued approval while it conducts another confirmatory trial.

Related Content

Topics

UsernamePublicRestriction

Register

PS053784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel